Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Healthcare Biotechnology
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Resverlogix Corp
Bullboard Posts
User Avatar Image
(2)
•••
Comment by toinv261on Feb 25, 2016 3:57pm
165 Views
Post# 24595808

RE:RE:RE:RE:RE:RVX Zenith and J Tull

RE:RE:RE:RE:RE:RVX Zenith and J TullG1945V...you are exactly right.

So what happens in investors eyes (or at least mine) is they say "oh, so you missed the the IPO in Q4 2015 and you expect me to believe your next claim (which is open ended and non committal)".

My point is that when potential investors experience this they put up caution flags and it applies to Resverlogix as well. Apabetalone (rvx-208) is in a phase 3 trial in EU countries and it probably should be trading above $5.00 but we sit at $1.30.

Anyway, I made my point and I won't beat this horse again. Thanks KBC for posting masilas (extremely helpful) notes. Always good to review what was said in order to get an accurate context.

There are so many exciting things happening at Zenith and RVX and the possibilities for both are incredible. Too bad the market doesn't see the potential.

GLTA
Toinv


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities